By Kevin Duffy, Chief Commercial Officer, KPS Life
There is continuous evaluation and varying opinion regarding the strategic resourcing models employed within the biopharmaceutical sector today. Notwithstanding the recent hurdles of COVID-19, understanding the human resource capital companies currently employ and the talent they hope to attract, is the foundation for creating effective strategies in workforce planning, proactive analytics, and overall talent supply chain management. The most viable of these strategies has been the utilization of a Functional Service Provider (FSP) model to augment and/or supplement in-house staff to meet the variable resource needs of a clinical operations team. This popular model was born on the heels of the various strategic partnering arrangements that evolved over time in the space and became a common offering within the outsourcing community. As a result of the many mergers and acquisitions in the space, very few pure-play, focused FSP providers remain on the landscape as the majority have been absorbed into large, ‘full-service offering’ CRO operations.